Tag:

Diabetes

Latest Headlines

Latest Headlines

Chinese drugmaker to build $60M API plant

Tonghua Dongbao Pharmaceutical will invest 367.2 million yuan ($59.21 million) to build a new facility to make insulin APIs, Reuters reported, citing a Chinese text press release from the country. The company, which already makes bulk insulin, needs the capacity to meet growing demand.

Takeda looks to settle thousands of Actos U.S. lawsuits for $2B

Takeda Pharmaceutical has offered $2.2 billion to settle all U.S. claims linked to its diabetes drug Actos as it battles thousands of cases and stretches legal resources even with some verdicts favorable, a report said April 1.

Glenmark on yo-yo string sales journey with diabetes generics in U.S.

Glenmark's marketing of a couple of diabetes generics in the United States continues to fluctuate like a yo-yo on a string. Now the India drugmaker can return the drugs to market until April 28.

Takeda touts CV data from alogliptin use in high-risk diabetes patients

Takeda Pharmaceutical said a post hoc study on alogliptin showed no increase in the composite rate of cardiovascular mortality and among high-risk patients with diabetes. The results were published in The Lancet.

U.S. biotech buying Belgian cell manufacturer for $25M

U.S.-based Orgenesis has been contracting for the sophisticated manufacturing capabilities of MaSTherCell as it moves to clinical trials with its process to reprogram human liver cells in people with Type 1 diabetes into insulin-producing cells. Now it will own them.

J&J joins forces with JDRF for Type 1 diabetes Dx

Johnson & Johnson's Janssen unit is teaming up with nonprofit JDRF to develop new diagnostic approaches for Type 1 diabetes, aiming to identify the disease earlier and curb its progression.

Cornell team engineers a probiotic GLP-1 therapy for diabetes

A group of researchers at Cornell says it engineered a human probiotic that also had a similar effect in controlling blood glucose levels in rat models for the disease. And a biotech has already snagged the license on this work as they set the stage to try it in humans.

International team tags a key brain pathway for hypoglycemia

A transatlantic team of researchers says that they have identified a new pathway in the brain that plays a critical role in signaling hypoglycemia. And they add that it's a solid target for drug researchers working in the blockbuster field.

China's Hua Medicine bags $25M for diabetes R&D

Shanghai's Hua Medicine hauled in a $25 million B round to advance its work on a new treatment for diabetes, bringing in investors from the U.S. and China as it moves toward late-stage development.

Mouse study points to a particular T cell target for diabetes, insulin resistance

Investigators at Baylor College of Medicine say that new animal research indicates that a certain type of T cell found in the immune system could be a good target for drug developers spotlighting Type 2 diabetes triggered by obesity as well as insulin resistance.